Welcome to our dedicated page for Quantum BioPharma SEC filings (Ticker: QNTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quantum BioPharma Ltd. (QNTM) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer in the United States. Quantum BioPharma submits Form 6-K reports under the Securities Exchange Act of 1934, which include press releases, condensed consolidated interim financial statements, management’s discussion and analysis of financial condition and results of operations, material change reports, information circulars, and voting results. These documents give investors insight into the company’s biopharmaceutical activities in neurodegenerative and metabolic disorders and alcohol misuse disorders, as well as its capital markets and corporate actions.
Recent Form 6-K filings incorporate financial statements and MD&A for periods ended September 30, 2025, along with CEO and CFO certificates and related XBRL data. Other 6-Ks attach press releases covering topics such as clinical progress with Lucid-21-302 (Lucid-MS), at-the-market offering agreements, private placements, warrant expirations, and updates on the company’s digital asset portfolio. Additional filings include material change reports and management information circulars that document corporate decisions, shareholder meetings, and changes reported under Canadian securities rules but furnished to the SEC for U.S. investors.
Through these filings, users can review how Quantum BioPharma describes its lead MS program, licensing arrangements for unbuzzd , strategic investments via FSD Strategic Investments Inc., and litigation-linked contingent value rights (CVRs). The filings also reference the company’s registration statement on Form F-3, into which certain 6-K exhibits are incorporated by reference. On Stock Titan, these documents are updated from EDGAR in near real time and are accompanied by AI-powered summaries that highlight key points from each report, helping readers quickly understand financial disclosures, clinical milestones, capital structure changes, and other material information without reading every page.
Investors can use this filings page to locate Quantum BioPharma’s quarterly financial information, narrative analysis, press releases furnished as exhibits, and other regulatory documents that together outline the company’s operations, risk factors referenced in its Canadian and U.S. disclosures, and the evolution of its MS, alcohol health, and investment activities.
Quantum BioPharma Ltd. has submitted an Investigational New Drug (IND) application to the U.S. FDA for Lucid-21-302 (Lucid-MS), a first-in-class drug candidate for multiple sclerosis. The filing supports a planned Phase 2 clinical trial targeting demyelination, a core driver of MS progression.
The IND package includes nonclinical pharmacology, toxicology, manufacturing and quality data. Phase 1 trials of Lucid-MS were completed and described as safe and well-tolerated. Quantum outlines an expected timeline with FDA feedback and Phase 2 trial initiation targeted for Q2 2026 and interim Phase 2 data projected in Q4 2026.
The company highlights MS as a major global market, citing 2.8 million patients worldwide and a therapeutic market projected to exceed $38 billion by 2030. It also describes a diversified business model combining clinical development of Lucid-MS with consumer health revenues from UNBUZZD™ via a 7% royalty structure and retained economic rights.
Quantum BioPharma Ltd. has signed a binding Letter of Intent with global CRO Allucent to support a planned Phase 2 clinical trial of Lucid-21-302 (Lucid-MS) for multiple sclerosis. The company expects to initiate this Phase 2 study in the second quarter of 2026, subject to regulatory approvals and finalization of the clinical trial design and operations.
Lucid-MS is described as a first-in-class new chemical entity aimed at providing neuroprotection by inhibiting demyelination, a key driver of MS progression, offering a differentiated approach versus immune-modulating therapies. The release highlights an MS prevalence of about 2.8 million people worldwide and a therapeutic market projected to exceed $38 billion by 2030.
Quantum BioPharma also outlines its broader portfolio, including a 19.84% ownership (as of December 31, 2025) in Unbuzzd Wellness Inc., rights to royalties of 7% of unbuzzd™ sales until a total of $250 million is paid and 3% thereafter, and a tax loss carry forward of approximately C$130 million that could offset future taxable profits.
Quantum BioPharma Ltd., an Ontario-based biotechnology company listed on Nasdaq through its Class B Subordinate Voting Shares, files its annual Form 20-F for the year ended December 31, 2025. The report is prepared under IFRS and not U.S. GAAP.
The company has no approved pharmaceutical products and is focused on developing Lucid-MS, a patented new chemical entity targeting multiple sclerosis, alongside licensed consumer brand unbuzzd™. It highlights extensive forward-looking and future-oriented financial information disclaimers and emphasizes that investors face substantial risk, including the possibility of a significant or total loss of capital.
Key risks span clinical uncertainty, regulatory approvals in multiple jurisdictions, commercialization hurdles, reliance on critical licenses (including with University Health Network and Unbuzzd), manufacturing and supply-chain challenges, strong competition from existing MS therapies, and extensive intellectual property, product liability, and compliance exposures typical of early-stage drug developers.
Quantum BioPharma Ltd. filed a Form 6-K highlighting a clinical and strategic update. The company has appointed internationally recognized MS specialist Dr. Salvatore Napoli as Principal Investigator for its planned Phase 2 trial of Lucid-21-302 (Lucid-MS) in multiple sclerosis.
Quantum BioPharma plans to submit an IND application for Lucid-MS to the U.S. FDA, with the proposed study assessing efficacy, safety, and tolerability in people with MS. Lucid-MS is described as a first-in-class, non-immunomodulatory neuroprotective compound and patented new chemical entity that has prevented demyelination in preclinical models.
The company also outlines its broader business: it retains 19.86% ownership of Unbuzzd Wellness Inc. as of September 30, 2025, with a 7% royalty on unbuzzd™ sales until $250 million in cumulative payments, then 3% in perpetuity, and holds approximately C$130 million in tax loss carryforwards.
Quantum BioPharma Ltd. reports that a peer-reviewed journal has published a double-blind, randomized, placebo-controlled crossover clinical trial of its dietary supplement unbuzzd, which is designed to be taken after reaching alcohol intoxication. The study in healthy adults found that unbuzzd reduced blood alcohol concentration on average more than 40 percent faster within the first 30 minutes than placebo, lessened heart rate and blood pressure changes, and eased perceived impairment, mental fatigue, and hangover symptoms, with no reported adverse side effects. Quantum BioPharma invented UNBUZZD and licensed its formula to Unbuzzd Wellness Inc., retaining 19.86% ownership as of September 30, 2025 and a 7% royalty on unbuzzd sales until total payments reach $250 million, after which the royalty falls to 3% in perpetuity. The company also notes an approximate C$130 million tax loss carryforward and highlights its broader pipeline, including Lucid-MS for multiple sclerosis.
Quantum Biopharma Ltd. received an amended Schedule 13G/A (Amendment No. 8) from Malone Wealth Ventures LLC reporting substantial ownership of its common stock. Malone Wealth Ventures reports beneficial ownership of 375,752 shares, representing 9.8% of the outstanding common shares.
The firm has sole power to vote 92,180 shares and sole power to dispose of 375,752 shares. The filing explains that these securities are held for clients of Malone Wealth Ventures, who have rights to dividends and sale proceeds, and states the holdings are in the ordinary course of business, not to influence control of the company.
Quantum Biopharma Ltd. filed an amended foreign issuer report to add a previously issued press release as an exhibit. The release announces the termination of its October 31, 2025 at-the-market offering agreement with H.C. Wainwright & Co., and is described in the exhibit index as relating to the closing of a private placement and a corporate update. Aside from furnishing this exhibit, the company states that the original report’s disclosures are unchanged.